Explore the growing U.S. Zilbrysq (Zilucoplan) market, projected to expand at a CAGR of 21.64% post-FDA approval for anti-AChR antibody-positive generalized myasthenia gravis (gMG). The subcutaneous ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

(Sharecast News) - London stocks ended lower on Monday, erasing earlier gains as investors reassessed the weekend's trade agreement between the United States and the European Union. The FTSE 100 index ...